Published in Women's Health Law Weekly, January 27th, 2008
The Phase 1a trial was a randomized, placebo-controlled, double-blind, single-ascending dose trial in 90 healthy male and female volunteers. Doses originally intended for study ranged from 1 mg to 160 mg, but due to excellent tolerability the maximum dose was increased to 320 mg. Doses were well...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly